Is bendamustine effective therapy in patients with rituximab-refractory , indolent B-cell non-Hodgkin lymphoma : results from a Multicenter Study?
Single-agent bendamustine produced a high rate of objective responses with acceptable toxicity in patients with recurrent, rituximab-refractory indolent B-cell lymphoma.
An oral dose of telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated first-line treatment for mild to moderate CAP in adults.